logo
  

Anadarko Petroleum Posts Q1 Adj. Loss Of $0.72/shr - Quick Facts

Anadarko Petroleum Corporation (APC) reported a first-quarter net loss attributable to common stockholders of $3.27 billion, or $6.45 per share, compared to a loss of $2.67 billion or $5.30 per share, prior year. The company noted that the net loss included certain items typically excluded by the investment community in published estimates, which in aggregate decreased earnings by $2.90 billion or $5.73 per share on an after-tax basis. Adjusted net loss was $365 million or $0.72 per share, for the quarter.

On average, 34 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.65 for the quarter. Analysts' estimates typically exclude special items.

Total revenue decreased to $2.32 billion from $5.84 billion last year. Analysts expected revenue of $2.52 billion for the quarter.

Sales volumes of natural gas, crude oil and natural gas liquids (NGLs) totaled a record 83 million BOE, or an average of 920,000 BOE per day, on a divestiture-adjusted basis.

"The significant cost savings, outstanding well performance and ongoing efficiency gains we achieved during the first quarter enabled Anadarko to deliver higher sales volumes for lower costs," said Al Walker, Anadarko Chairman, President and CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT